Kura Oncology (KURA) Cash from Financing Activities (2010 - 2026)

Kura Oncology (KURA) has 15 years of Cash from Financing Activities data on file, last reported at $69000.0 in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 51.75% year-over-year to $69000.0 in Q1 2026; TTM through Mar 2026 was $1.7 million, a 72.23% decrease from a year earlier, with the FY2025 full-year figure at $1.8 million, down 98.84% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $69000.0, down from $1.1 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for KURA reached as high as $148.4 million in Q1 2024 and fell as low as $69000.0 in Q1 2026.
• Historically, Cash from Financing Activities has averaged $14.0 million across 5 years, with a median of $843000.0 in 2022.
• Across the five-year window, Cash from Financing Activities soared 4271.91% in 2022 and sank 99.9% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $34.7 million in 2022, then slumped by 98.01% to $691000.0 in 2023, then rose by 16.64% to $806000.0 in 2024, then jumped by 40.82% to $1.1 million in 2025, then tumbled by 93.92% to $69000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $69000.0 in Q1 2026, $1.1 million in Q4 2025, and $515000.0 in Q2 2025.